Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Viscosupplementation Market – Insights

Viscosupplementation is a minimally invasive procedure that involves injection of the hyaluronic acid injected into a knee joint to promote better joint development and lubrication. It also helps in reducing pain, irritation and helps in improving osteoarthritis condition. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Increasing prevalence of osteoarthritis in people is expected to boost demand for the viscosupplementation products.  

The global viscosupplementation market is estimated to be valued at US$ 2,524.8 Mn in 2019 and is expected to increase to US$ 4,738.8 Mn by 2027, witnessing a CAGR of 8.2% over the forecast period (2019-2027).

Figure 1. Global Viscosupplementation Market Share (%), By Treatment (2019 & 2027)

Viscosupplementation  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing product launches and regulatory approval of viscosupplementation products are expected to drive the global viscosupplementation market growth

Increasing demand for viscosupplementation products has encouraged manufacturers to focus on the development of innovative viscosupplementation products and launching them in the market.  For instance, in March 2018, Bioventus, a provider of orthobiologic solutions, launched DUROLANE, which is a single-injection hyaluronic acid (HA) product used for joints-lubrication as treatment for pain associated with knee osteoarthritis (OA). Moreover, in October 2018, Bioventus received the Agência Nacional de Vigilância Sanitària (ANVISA) approval for marketing DUROLANE, in Brazil.

Furthermore, in February 2014, Anika Therapeutics, Inc. received marketing approval from the U.S. Food and Drug Administration (FDA), for its product MONOVISC, a single injection viscosupplement indicated for treatment of patients with osteoarthritis.

Rising prevalence of osteoarthritis and other joint pain conditions is driving demand for viscosupplementation products, which is expected to facilitate growth of the global viscosupplementation market during the forecast period

Hyaluronic acid injections are usually prescribed when patients suffering from osteoarthritis are not getting adequate relief from a simple analgesic or drug treatment. Hyaluronic acid injection is given in the knee to fulfill the need of hyaluronate (naturally produced by body) in synovial fluid for proper functioning and lubrication. Moreover increasing prevalence of knee osteoarthritis and hip osteoarthritis has led to an increase in demand for viscosupplementation products. For instance, according to the National Center for Biotechnology Information (NCBI), in 2014, osteoarthritis was the most common joint disorder in the U.S., and occurred more in women compared to men. For instance, prevalence of knee osteoarthritis (KOA) is around 10% in men and 13% in women aged 60 years or older.

Key players are focusing on building a strong distribution network through adoption of several inorganic strategies to enhance and expand their viscosupplementation product portfolio

Increasing demand and usage of viscosupplementation products has influenced major players to expand their product portfolio and strengthen their position in the market. This has led manufacturers to adopt inorganic growth strategies such as distribution agreement and collaborations. For instance, in November 2016, Seikagaku Corporation entered into an exclusive distribution agreement with Zimmer Biomet Holdings for its product VISCO-3, a hyaluronic acid-based viscosupplement product indicated for the treatment of knee osteoarthritis pain, in the U.S.

Moreover, Ferring Pharmaceuticals has a wide sales and distribution network, with distributors in more than 40 countries.

Global Viscosupplementation Market - Regional Analysis

Regional segmentation of the global viscosupplementation market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth over the forecast period owing to increasing prevalence of osteoarthritis in the region. For instance, according to the Centers for Disease Control and Prevention’s (CDC) report, osteoarthritis affected more than 30 million U.S adults during 2018, and it has been estimated that 70 million people are likely to suffer from osteoarthritis by 2040.

Asia Pacific is also expected to witness growth in the global viscosupplementation market owing to increasing regulatory approvals of viscosupplementation products in the region. For instance, in July 2017, Anika Therapeutics, Inc. received approval for MONOVISC from regulatory authorities in India and Australia. MONOVISC is a single-injection viscosupplement for pain associated with osteoarthritis of all human synovial joints.

Figure 2:  Global Viscosupplementation Market Value (US$ Mn) Analysis and Forecast & Y-o-Y Growth (%)

Viscosupplementation  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

One of the major factors restraining the viscosupplementation market growth is higher cost of viscosupplementation products, which may not be affordable among lower income populations. For instance, according to the National Center for Biotechnology Information (NCBI), viscosupplementation injections such as Monovisc are priced at US$ 320 per injection, Durolane at US$ 409 per injection, and Synvisc-One at US$ 424 per injection, Cingal US$ 400 per injection and others.

Global Viscosupplementation Market - Key Players

Key players covered as a part of this market are Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.

Viscosupplementation is a treatment that helps in reducing the joint pain, and improves the functional condition of the osteoarthritic joint. It involves the injection of a thick fluid called hyaluronic acid into the knee. Hyaluronic acid (HA) is found in the synovial fluid that lubricates the cartilage surfaces and protects the joints from shock. HA is an elastic substance naturally secreted by mesothelial cells. Osteoarthritis is the most common type of arthritis characterized by loss of function and degeneration of cartilage and tissues that cover the ends of the bones in a joint.

Market Dynamics

Rising prevalence of osteoarthritis such as knee osteoarthritis, hip osteoarthritis, tennis elbow, joint pain and others are orthopedic disorders that are expected to augment the global viscosupplementation market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), osteoarthritis (OA) is the most common joint disorder in the U.S. For instance, from 2013- 2015, on an annual basis, an estimated 54.4 million adults in the U.S. were diagnosed with osteoarthritis, among which 7.1% were in the age group of 18 to 44 years, 29.3% people were aged between 45 to 64 years, and 49.6% people were in the age group of 65 years or older.

Increasing adoption of inorganic strategies such as collaborations and partnerships by manufacturers is expected to drive the global viscosupplementation market growth over the forecast period.

Manufactures are engaged in adopting strategies such as collaborations and partnership agreements in order to expand their distribution network and carry out production, research and development activities to produce new innovative products in the market. For instance, in May 2016, Anika Therapeutics formed a commercialization partnership with Pendopharm, a division of Pharmascience Inc., to sell Anika Therapeutics' product CINGAL, in Canada.

Key features of the study:

  • This report provides in-depth analysis of the global viscosupplementation market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period: 2019- 2027, considering 2018 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global viscosupplementation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, end user upgrades, market expansion, and marketing tactics
  • The global viscosupplementation market report caters to various stakeholders in this industry, including investors, device/system manufacturers, distributors and suppliers for viscosupplimentation products, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the viscosupplementation market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation

  • Global Viscosupplementation Market, By Treatment:
    • Single Injection Treatment Cycle
    • Three Injection Treatment Cycle
    • Five Injection Treatment Cycle
  •  Global Viscosupplementation Market, By Application:
    • Knee Osteoarthritis
    • Hip Osteoarthritis
    • Others
  • Global Viscosupplementation Market, By Region:
    • North America
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Latin America
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Asia Pacific
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment:
        • Single Injection Treatment Cycle
        • Three Injection Treatment Cycle
        • Five Injection Treatment Cycle
      • By Application:
        • Knee Osteoarthritis
        • Hip Osteoarthritis
        • Others
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Anika Therapeutics Inc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Strategies
    • Seikagaku Corporation
    • Ferring Pharmaceuticals
    • Bioventus
    • Fidia Farmaceutici S.P.A.
    • Mylan N.V.
    • Sanofi S.A.
    • ORTHOGENRX
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
    • Industry Trend
    • Mergers and Acquisitions
    • Technology Overview
    • Promotion Initiatives
  4. Global Viscosupplementation Market, By Treatment, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Single Injection Treatment Cycle
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Three Injection Treatment Cycle
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Five Injection Treatment Cycle
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  5. Global Viscosupplementation Market, By Application, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 - 2027
      • Segment Trends
    • Knee Osteoarthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Hip Osteoarthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  6. Global Viscosupplementation Market, By Region, 2016 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
    • North America
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment, 2016 – 2027 (US$ Mn)
      • Market Size and Forecast, By Application, 20176– 2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Anika Therapeutics Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Seikagaku Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Ferring Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bioventus
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Fidia Farmaceutici S.P.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • ORTHOGENRX
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 24 market data tables and 26 figures on "Viscosupplementation Market - Global forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner